Citations

Clear

390 citation(s) found for "Loftus, E".

Economic Burden of Fatigue in Inflammatory Bowel Disease
Ananthakrishnan, Ashwin N. , Desai, Raj , Lee, Wan‐Ju , Griffith, Jenny, Chen, Naijun, Loftus, Edward V. , Ananthakrishnan, A N , Loftus, Edward V

Mayo Clinic

Crohn's & Colitis 360 | April 20, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad020 | PMID 37663925 Get It

AbstractBackgroundThis retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD.MethodsEligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls.ResultsMatched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn’s disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P < .001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P < .001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P < .001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups.ConclusionsPresence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease
Vasudevan, Abhinav , Tharayil, Vivek, Raffals, Laura H., Bruining, David H. , Becker, Michelle , Murad, Mohammad Hassan, Murad, M. Hassan , Loftus, Edward V.

Mayo Clinic

Inflammatory Bowel Diseases | April 18, 2023 | Volume: 30 | Issue: 4 | Pages: 660-670

10.1093/ibd/izad065 | PMID 37071852 Get It

Abstract Background Optimizing therapy and monitoring response are integral aspects of inflammatory bowel disease treatment. We conducted a systematic review and meta-analysis to determine whether serum ustekinumab trough concentrations during maintenance therapy were associated with ustekinumab treatment response in patients with inflammatory bowel disease. Methods A systematic review was performed to March 21, 2022, to identify studies using MEDLINE, EMBASE, and the Cochrane library. We included studies that reported the association between serum ustekinumab trough concentrations with clinical or endoscopic remission. Outcome measures were combined across studies using the random-effects model with an odds ratio (OR) for binary outcomes of endoscopic and clinical remission. Results We identified 14 observational studies that were included in the analysis for clinical remission (919 patients, 63% with Crohn’s disease) or endoscopic remission (290 patients, all with Crohn’s disease). Median ustekinumab trough concentrations were higher amongst individuals achieving clinical remission compared with those not achieving remission (mean difference, 1.6 ug/mL; 95% confidence interval [CI], 0.21-3.01 ug/mL). Furthermore, individuals with median serum trough concentration in the fourth quartile were significantly more likely to achieve clinical (OR, 3.61; 95% CI, 2.11-6.20) but not endoscopic remission (OR, 4.67; 95% CI, 0.86-25.19) compared with those with first quartile median trough concentrations. Conclusion Based on the results of this meta-analysis primarily relating to patients with Crohn’s disease on maintenance ustekinumab treatment, it appears that there is an association between higher ustekinumab trough concentration and clinical outcomes. Prospective studies are required to determine whether proactive dose adjustments of ustekinumab therapy provides additional clinical benefit.
Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis
Kugelmas, Marcelo , Loftus, Michelle, Owen, Emily , Wadei, Hani M. , Saab, Sammy , Wadei, Hani, Wadei, Hani M

Mayo Clinic

American Journal of Health-System Pharmacy | April 4, 2023 | Volume: 80 | Issue: 13 | Pages: 806-817

10.1093/ajhp/zxad070 | PMID 37013893 Get It

Abstract Purpose Albumin, the most abundant and arguably most important protein in the human body, plays a unique role in decompensated cirrhosis because its structure and function are quantitatively and qualitatively affected. A literature review was performed to provide insights into albumin use. The manuscript was developed using a multidisciplinary approach; 2 hepatologists, a nephrologist, a hospitalist, and a pharmacist, who are all members of or work closely with the Chronic Liver Disease Foundation, collaborated to write this expert perspective review. Summary Cirrhosis represents the potential end in the spectrum of all chronic liver diseases. Decompensated cirrhosis, defined by the overt manifestation of liver failure (eg, ascites, hepatic encephalopathy, variceal bleeding), is the inflection point associated with increased mortality. Human serum albumin (HSA) infusion serves an important role in the treatment of advanced liver disease. The benefits of HSA administration in patients with cirrhosis are widely accepted, and its use has been advocated by several professional societies. However, inappropriate HSA use can lead to significant adverse patient events. This paper discusses the rationale for the administration of HSA in the treatment of complications of cirrhosis, analyzes the data on the use of HSA in cirrhosis, and streamlines practical recommendations set forth in published guidance. Conclusion Use of HSA in clinical practice needs to be improved. The objective of this paper is to empower pharmacists to facilitate and improve the use of HSA in patients with cirrhosis at their practice sites.
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Kemppainen, Jennifer L., Vitek, Carolyn R. Rohrer , Whalen, Denise A., Kolbert, Kayla J., Sikkink, Kaitlin J. , Kroc, Sarah A., Kruisselbrink, Teresa , Shupe, Gabrielle F., Knudson, Alyssa K., Burke, Elizabeth , Loftus, Elle C., Bandel, Lorelei A. , Prochnow, Carri A., Mulvihill, Lindsay A., Thomas, Brittany C. , Gamble, Dale M., Graddy, Courtney B., Garzon, Giovanna G. Moreno, Ekpoh, Idara U., Porquera, Eva M. Carmona, Hogan, Marie C. , Ters, Mireille El , Davis, III John M., Vella, Adrian, Kumar, Seema , Creo, Ana L. , Lteif, Aida, Pittock, Siobhán T. , Tebben, Peter J. , Abate, Ejigayehu G., Joshi, Avni Y. , Ristagno, Elizabeth H. , Patnaik, Mrinal S., Sabrowsky, Sonia M., Wierenga, Klaas J. , Keddis, Mira T. , Samadder, N. Jewel , Presutti, R. John , Stephens, Michael C., Roberts, Lewis R. , Faubion, William A. , Driscoll, Sherilyn W. , Selcen, Duygu , Jackson, Lauren , Ortega, Victor E. , Anderson, Sarah , Aoudia, Stacy L., Klee, Eric W. , McAllister, Tammy M., Carmona, Eva M. , Carmona, Eva M , Roberts, Lewis R , Presutti, Richard J , Tebben, Peter , Hogan, Marie C , Vairo, Filippo Pinto e , Burke, Elizabeth M., Fervenza, Fernando C. , Warrington, Kenneth J. , Koster, Matthew J. , Orandi, Amir B. , Basiaga, Matthew L. , Patnaik, Mrinal S., Schimmenti, Lisa A. , Dhamija, Radhika , Robinson, Steven I. , Wong‐Kisiel, Lily C. , Flanagan, Eoin P. , Ramanan, Vijay K. , Mauermann, Michelle L. , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617916/v1 Get It

Abstract Background In the United States, rare disease (RD) is defined as a condition that affects fewer than 200,000 individuals. Collectively, RD affects an estimated 30 million Americans. A significant portion of RD has an underlying genetic cause; however, this may go undiagnosed. To better serve these patients, the Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) was created under the auspices of the Center for Individualized Medicine (CIM) aiming to integrate genomics into subspecialty practice including targeted genetic testing, research, and education. Methods Patients were identified by subspecialty healthcare providers from 11 clinical divisions/departments. Targeted multi-gene panels or custom exome/genome-based panels were utilized. To support the goals of PRaUD, a new clinical service model, the Genetic Testing and Counseling (GTAC) unit, was established to improve access and increase efficiency for genetic test facilitation. The GTAC unit includes genetic counselors, genetic counseling assistants, genetic nurses, and a medical geneticist. Patients receive abbreviated point-of-care genetic counseling and testing through a partnership with subspecialty providers. Results Implementation of PRaUD began in 2018 and GTAC unit launched in 2020 to support program expansion. Currently, 29 RD clinical indications are included in 11 specialty divisions/departments with over 142 referring providers. To date, 1,152 patients have been evaluated with an overall solve rate of 14.1% and as high as 66.7% depending on the phenotype. Noteworthy, 42.7% of the solved or likely solved patients underwent changes in medical management and outcome based on genetic test results. Conclusion Implementation of PRaUD and GTAC have enabled subspecialty practices advance expertise in RD where genetic counselors have not historically been embedded in practice. Democratizing access to genetic testing and counseling can broaden the reach of patients with RD and increase the diagnostic yield of such indications leading to better medical management as well as expanding research opportunities.
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, Sarah K. , Damask, Cecelia, Ebert, Charles S. , Levy, Joshua M. , Lin, Sandra Y. , Luong, Amber , Rodriguez, Kenneth , Sedaghat, Ahmad R. , Toskala, Elina , Akdiş, Cezmi A. , Ansotegui, Ignacio J. , Azar, Antoine , Baroody, Fuad M. , Benninger, Michael S. , Casale, Thomas B. , Chaaban, Mohamad R. , Chew, Fook Tim , Chambliss, Jeffrey , Cianferoni, Antonella , Čustović, Adnan , Davis, Elizabeth Mahoney , DelGaudio, John M. , Flanagan, Carrie E. , Franzese, Christine B., Gill, Amarbir S. , Halderman, Ashleigh A. , Joe, Stephanie, Joshi, Shyam , Kuruvilla, Merin , Kim, Jean , Klein, Adam M. , Krouse, Helene J. , Lang, David M. , Laury, Adrienne M., Lee, Victoria S. , Loftus, Patricia A. , Marzouk, Haidy, Mims, James W., Oppenheimer, John , Orlandi, Richard R. , Phillips, Katie M. , Raymond, Mallory , Ryan, Matthew W., Sastre, J. , Schlosser, Rodney J. , Shaker, Marcus , Smith, Kristine A. , Soyka, Michael , Tang, Monica , Tantilipikorn, Pongsakorn , Taw, Malcolm B., Tversky, Jody , Tyler, Matthew A. , Veling, Maria C., Wallace, Dana , White, Andrew A. , Roland, Lauren T , Levy, Joshua M , Luong, Amber U , Sedaghat, Ahmad R , Villwock, Jennifer , Abdullah, Baharudin , Alt, Jeremiah A , Chaaban, Mohamad R , Gill, Amarbir , Kuruvilla, Merin Elizabeth , Kim, Jean , Kuan, Edward C , Lee, Victoria S , Marcus, Sonya , Mattos, Jose , McCoul, Edward D , Nayak, Jayakar V , Orlandi, Richard , Schuman, Theodore A , Smith, Kristine , Soyka, Michael B , Tantilipikorn, Pongsakorn , Tyler, Matthew A , Zhang, Luo , Schlosser, Rodney J , Chew, Fook Tim , Casale, Thomas , Alt, Jeremiah A. , Bernstein, Jonathan A. , Brook, Christopher D. , Campbell, Raewyn Gay , Ellis, Anne K. , Fokkens, Wytske Johanna , Greenhawt, Matthew , Hohlfeld, Jens Michael , Incorvaia, Cristoforo , Larenas‐Linnemann, Désirée E. , Lechner, Matt , Lee, Stella E. , Mattos, José L. , McCoul, Edward D. , Melén, Erik , Mullol, Joaquim , Nayak, Jayakar V. , Platt, Michael P. , Ramanathan, Murugappan , Raymond, Mallory J , Rhee, Chae‐Seo , Reitsma, Sietze , Sheikh, Aziz , Takashima, Masayoshi , Wang, De Yun , Zhang, Luo

Mayo Clinic

International Forum of Allergy & Rhinology | March 6, 2023 | Volume: 13 | Issue: 4 | Pages: 293-859

10.1002/alr.23090 | PMID 36878860 Get It

Abstract Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
The Incidence of Pouch Neoplasia Following Ileal Pouch–Anal Anastomosis in Patients With Inflammatory Bowel Disease
Urquhart, Siri A. , Comstock, Bryce, Jin, Mauricio F. , Day, Courtney N. , Eaton, John E. , Harmsen, William S. , Raffals, Laura E. , Coelho–Prabhu, Nayantara , Comstock, Bryce P, Coelho-Prabhu, Nayantara , Loftus, Edward V.

Mayo Clinic

Inflammatory Bowel Diseases | February 22, 2023 | Volume: 30 | Issue: 2 | Pages: 183-189

10.1093/ibd/izad021 | PMID 36812365 Get It

Abstract Background Ileal pouch–anal anastomosis (IPAA) is the standard restorative procedure following proctocolectomy in patients with inflammatory bowel disease (IBD) who require colectomy. However, removal of the diseased colon does not eliminate the risk of pouch neoplasia. We aimed to assess the incidence of pouch neoplasia in IBD patients following IPAA. Methods All patients at a large tertiary center with International Classification of Diseases–Ninth Revision/International Classification of Diseases–Tenth Revision codes for IBD who underwent IPAA and had subsequent pouchoscopy were identified using a clinical notes search from January 1981 to February 2020. Relevant demographic, clinical, endoscopic, and histologic data were abstracted. Results In total, 1319 patients were included (43.9% women). Most had ulcerative colitis (95.2%). Out of 1319 patients, 10 (0.8%) developed neoplasia following IPAA. Neoplasia of the pouch was seen in 4 cases with neoplasia of the cuff or rectum seen in 5 cases. One patient had neoplasia of the prepouch, pouch, and cuff. Types of neoplasia included low-grade dysplasia (n = 7), high-grade dysplasia (n = 1), colorectal cancer (n = 1), and mucosa-associated lymphoid tissue lymphoma (n = 1). Presence of extensive colitis, primary sclerosing cholangitis, backwash ileitis, and rectal dysplasia at the time of IPAA were significantly associated with increased risk of pouch neoplasia. Conclusions The incidence of pouch neoplasia in IBD patients who have undergone IPAA is relatively low. Extensive colitis, primary sclerosing cholangitis, and backwash ileitis prior to IPAA and rectal dysplasia at the time of IPAA raise the risk of pouch neoplasia significantly. A limited surveillance program might be appropriate for patients with IPAA even with a history of colorectal neoplasia.
Comorbid extra‐intestinal central sensitization conditions worsen irritable bowel syndrome in primary care patients
Wang, Xiao Jing , Ebbert, Jon O. , Loftus, Connor G., Rosedahl, Jordan K., Wang, Xiao Jing , Philpot, Lindsey M.

Mayo Clinic

Neurogastroenterology & Motility | February 20, 2023 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/nmo.14546 | PMID 36807964 Get It

AbstractBackgroundIrritable bowel syndrome (IBS) is characterized as a central sensitization syndrome (CSS), a group of conditions including fibromyalgia, chronic fatigue, and restless leg syndrome (RLS) among others with frequent comorbidities of anxiety, depression, and chemical sensitivity. The prevalence of comorbid conditions and their impact on IBS symptom severity and quality of life in rural community populations has not been described.MethodsWe administered a cross‐sectional survey to patients with a documented CSS diagnosis in rural primary care practices to evaluate the relationship between CSS diagnoses, quality of life, symptom severity, and interactions with healthcare providers utilizing validated questionnaires. Subgroup analysis was performed on the IBS cohort. Mayo Clinic IRB approved the study.Key ResultsSeven hundred seventy‐five individuals out of 5000 completed the survey (15.5% response rate) with 264 (34%) reporting IBS. Only 3% (n = 8) of IBS patients reported IBS alone without comorbid CSS condition. Most respondents reported overlapping migraine (196, 74%), depression (183, 69%), anxiety (171, 64%), and fibromyalgia (139, 52%). IBS patients with more than two comorbid CS condition showed significantly higher symptom severity with linear increase. Quality of life was lower in IBS with comorbid conditions, particularly in patients with IBS and RLS (mean EQ5‐D 0.36 vs. 0.8 in IBS only, p < 0.01). Quality of life declined as number of comorbid conditions increased.Conclusions & InferencesPatients with IBS often have multiple CS disorders which increases symptom severity and lowers quality of life. Understanding the impact of multiple CSS diagnoses and treating these as a global condition may improve patient experience.
Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn’s Disease
Johnson, Amanda M. , Harmsen, William S. , Tremaine, William J., Raffals, Laura E. , Harmsen, William Scott, Aniwan, Satimai , Dayyeh, Barham K. Abu , Loftus, Edward V.

Mayo Clinic

Journal of Clinical Gastroenterology | February 2, 2023 | Volume: 58 | Issue: 2 | Pages: 176-182

10.1097/mcg.0000000000001821 | PMID 36728679 Get It

Background: Obesity is on the rise within the inflammatory bowel disease population. The impact obesity has on the natural history of Crohn’s disease (CD) is not well-understood. We aimed to describe the prevalence of obesity in a population-based cohort of newly diagnosed patients with CD, and the impact obesity had on disease phenotype and outcomes of corticosteroid use, hospitalization, intestinal resection, and development of fistulizing or penetrating disease. Materials and Methods: A chart review was performed on Olmsted County, Minnesota residents diagnosed with CD between 1970 and 2010. Data were collected on demographics, body mass index, CD location and behavior, CD-related hospitalizations, corticosteroid use, and intestinal resection. The proportion of individuals considered obese at the time of CD diagnosis was evaluated over time, and CD-associated complications were assessed with Kaplan-Meier survival analysis. Results: We identified 334 individuals diagnosed with CD between 1970 and 2010, of whom 156 (46.7%) were either overweight (27.8%) or obese (18.9%) at the time of diagnosis. The proportion of patients considered obese at the time of their diagnosis of CD increased 2-3 fold over the course of the study period. However, obesity did not have a significant impact on the future risk of corticosteroid use, hospitalization, intestinal resection, or development of penetrating and stricturing complications. Conclusions: Obesity is on the rise in patients with CD, although in this cohort, there did not appear to be any negative association with future CD-related outcomes. Further prospective studies, ideally including obesity measures such as visceral adipose tissue assessment, are warranted to understand the implications of the rising prevalence of obesity on CD outcomes.
P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1
Khan, R M Q, Ananthakrishnan, A, Iroku, Ugonna, Mukherjee, R, Uddin, Sharif , Odufalu, Florence-Damilola , Liu, J, Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i977-i979

10.1093/ecco-jcc/jjac190.0984 Get It

Abstract Background The incidence of inflammatory bowel disease (IBD) has risen among Black individuals and Hispanic or Latino individuals in the USA in recent decades; however, these patients are underrepresented in clinical trials of IBD therapies. We aimed to perform a post hoc analysis of the baseline demographics and clinical characteristics in three phase 3 clinical trials of vedolizumab for ulcerative colitis (UC) to identify differences between racial and ethnic groups. Methods The baseline demographics and clinical characteristics of patients with UC who were enrolled in GEMINI 1, VARSITY, and VISIBLE 1 were pooled and stratified by race and ethnicity, which were self-reported. The inclusion criteria for these trials included adult patients with moderately to severely active UC who had a prior inadequate treatment response, loss of response, or intolerance to conventional therapies or anti-tumour necrosis factor α treatment. Data were analysed using descriptive statistics, with mean or median values calculated for continuous variables, and the number and proportion of patients reported for categorical variables. T-tests and exact tests were used to compare continuous and categorical variables, respectively, between Black and White patients and between Hispanic or Latino patients and those who were not Hispanic or Latino. Results We included 1,358 patients, of whom 1,171 (86.2%) were White, 148 (10.9%) were Asian, 14 (1.0%) were Black, and 25 (1.8%) were of multiple or unspecified racial groups (Table 1). Black patients had significantly higher mean weight (87.9 kg vs 74.8 kg, p &lt; 0.01) and body mass index (30.5 kg/m2 vs 25.2 kg/m2, p &lt; 0.01), but lower albumin (38.5 g/L vs 41.2 g/L, p &lt; 0.05) and haemoglobin levels (115.5 g/L vs 126.1 g/L, p &lt; 0.05) than White patients (Table 1). Ethnicity data were recorded for 465 patients (34.2%). Hispanic or Latino patients were shorter in height (166.6 cm vs 171.0 cm, p &lt; 0.01) and had shorter mean disease duration (4.6 years vs 7.6 years, p &lt; 0.01) than those who were not Hispanic or Latino (Table 2). A non-significant, but numerically greater proportion of Hispanic or Latino patients had pancolitis than those who were not Hispanic or Latino (50.0% vs 35.8%). Conclusion In this post hoc analysis of vedolizumab clinical trials, Black patients and Hispanic or Latino patients with UC had differences in certain demographic and disease characteristics versus White patients and patients who were not Hispanic or Latino, respectively. These differences may have implications for therapy. Thus, inclusion of a more diverse patient population that reflects the demographics of the general population is warranted to adequately ascertain drug efficacy across racial and ethnic groups.